Tiger Brokers

BRIEF-Innovent Biologics Says Co And Takeda Will Co-Develop IBI363 (Pd-1/Il-2Α-Bias) Globally And Co-Commercialize It In U.S.

Reuters
Oct 22
BRIEF-<a href="https://laohu8.com/S/IVBIY">Innovent Biologics</a> Says Co And Takeda Will Co-Develop IBI363 (Pd-1/Il-2Α-Bias) Globally And Co-Commercialize It In U.S.

Oct 22 (Reuters) - Innovent Biologics Inc 1801.HK:

  • INNOVENT AND TAKEDA WILL CO-DEVELOP IBI363 PD-1/IL-2Α-BIAS) GLOBALLY AND CO-COMMERCIALIZE IT IN U.S.

  • WILL RECEIVE $1.2 BILLION UPFRONT PAYMENT, INCLUDING STRATEGIC EQUITY INVESTMENT OF $100 MILLION BY WAY OF SUBSCRIPTION

  • CO ALSO ELIGIBLE FOR POTENTIAL MILESTONES TOTALING UP TO $10.2 BILLION

Further company coverage: 1801.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10